U.S. Retail REITs Stock News

Some EOG Resources, Inc. ( NYSE:EOG ) shareholders may be a little concerned to see that the CEO & Chairman, Ezra...

Insiders who purchased US$207.4k worth of The Hain Celestial Group, Inc. ( NASDAQ:HAIN ) shares over the past year...

We wouldn't blame Aveanna Healthcare Holdings Inc. ( NASDAQ:AVAH ) shareholders if they were a little worried about the...

We wouldn't blame T. Rowe Price Group, Inc. ( NASDAQ:TROW ) shareholders if they were a little worried about the fact...

Some Starling Oncology, Inc. ( NASDAQ:STLN ) shareholders may be a little concerned to see that the Vice Chairman...

DexCom stock has delivered a decline of about 35% over the past 5 years, yet a Discounted Cash Flow (DCF) intrinsic value estimate currently points to meaningful upside compared with the recent US$88.96 share price. At the same time, the broader valuation checks lean expensive overall, which leaves investors weighing a discounted intrinsic estimate against a weaker score on other metrics. Over the past 5 years, DexCom shares are down roughly 35%, which means long term holders have so far not...

Casella Waste Systems (CWST) is back on investor radars after recent share price moves, with the stock closing at $93.74. That is putting fresh attention on how its fundamentals line up today. Recent moves in Casella Waste Systems reflect a stock that has picked up some short term momentum, with a 30 day share price return of 4.97% and a 90 day share price return of 11.30%. However, total shareholder return over the past year is still down 6.41%, while the 5 year total shareholder return of...

Crown Castle stock has fallen sharply over the past few years, yet current valuation checks suggest the market price may sit below a reasonable intrinsic value estimate based on its cash flow outlook. With both the Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples pointing to undervaluation, investors are weighing whether the recent share price weakness has already more than accounted for the key risks. Crown Castle shares are down about 51.5% over 5 years, which...

We wouldn't blame Danaher Corporation ( NYSE:DHR ) shareholders if they were a little worried about the fact that...

Johnson & Johnson (JNJ) shares are trading against the backdrop of a fresh U.S. Food and Drug Administration approval for Imaavy, the first and only treatment specifically cleared for warm autoimmune hemolytic anemia. Despite the short term share price pullback of around 1% on the day of the Imaavy announcement, Johnson & Johnson’s recent approvals in wAIHA and atrial fibrillation come against a stronger backdrop. The 90 day share price return of 16.98% and the 1 year total shareholder return...

Home Depot stock is caught between two very different valuation reads right now, with a Discounted Cash Flow (DCF) intrinsic value estimate suggesting the shares trade at a premium, while market based multiples still point to a discount relative to fundamentals. That split comes after a 5 year return that is positive but not extreme, which leaves investors weighing how much optimism is already reflected in the current price. Home Depot has returned about 16.6% over the past 5 years, which...

Anyone interested in FVCBankcorp, Inc. ( NASDAQ:FVCB ) should probably be aware that the Independent Director, Scott...

Pitney Bowes Inc. recently launched cash-funded tender offers to buy back up to US$50,000,000 of its 6.70% Notes due 2043 and 5.250% Medium-Term Notes due 2037, with the offers scheduled to expire on September 18, 2026. This move to retire a portion of its long-dated debt using cash on hand could reshape Pitney Bowes’ balance sheet and interest expense profile. Now we’ll examine how this cash-funded reduction of long-dated debt affects Pitney Bowes’ investment narrative and future capital...

IonQ stock has delivered a very large 5 year gain, yet on broad valuation checks it currently screens as expensive rather than a clear bargain. With fresh news around space focused optical terminals, new quantum chemistry tools and manufacturing expansion, investors are weighing how much of IonQ’s story is already reflected in the share price. Over 5 years, IonQ has returned about 301.5% which puts recent share price weakness into context and raises the question of how much long term upside...

Sticky July PCE inflation and a divided Federal Reserve keep markets on edge, while softer retail sales hint that consumers may be slowing down. That mix can punish some stocks and reward others, especially companies with steadier cash flows and dividends. This article looks at three high quality dividend stocks that appear closely linked to these cross currents and explains how the latest data could shape their risk and reward profile for your portfolio. The three dividend stocks below are...

Fabrinet (FN) stock is in focus after the company reported record fourth quarter results, with revenue of $1.316b and higher earnings per share, alongside fresh guidance and a revised revenue reporting structure. Despite Fabrinet's strong Q4 2026 report and new revenue guidance, the stock has pulled back recently, with a 30 day share price return of down 7% and a 90 day share price return of down 34.5% from recent highs. At the same time, the 1 year total shareholder return is 31.7% and the 5...

Even if it's not a huge purchase, we think it was good to see that James Barber, the Director of Gevo, Inc...

Mizuho’s recent initiation of coverage on Talen Energy (TLN) on August 24 put fresh attention on the stock, following the Cornerstone acquisition, which reshaped its generation profile and updated guidance that highlighted expectations for future free cash flow. For context, Talen Energy’s share price is US$306.29, with the stock down 6% over the past month and 23% year to date. The 3 year total shareholder return is very large, which points to strong earlier gains even as recent momentum has...

Anyone interested in Backblaze, Inc. ( NASDAQ:BLZE ) should probably be aware that the Co-Founder, Gleb Budman...

Gilead Sciences (NasdaqGS:GILD) received European Commission approval for Trodelvy plus Keytruda as a first-line treatment for metastatic triple-negative breast cancer across all PD-L1 statuses in Europe. The decision makes Trodelvy plus Keytruda the only approved antibody-drug conjugate and immunotherapy combination for first-line metastatic triple-negative breast cancer patients in the region. The approval broadens access to Trodelvy for a wider metastatic triple-negative breast cancer...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

We'd be surprised if Spire Global, Inc. ( NYSE:SPIR ) shareholders haven't noticed that the Independent Director...

Herc Holdings Inc. ( NYSE:HRI ) shareholders (or potential shareholders) will be happy to see that the Director, Erik...

The recent 29% drop in SelectQuote, Inc.'s ( NYSE:SLQT ) stock could come as a blow to insiders who purchased US$105.0k...